Your browser is no longer supported. Please, upgrade your browser.
XPH SPDR S&P Pharmaceuticals ETF daily Stock Chart
SPDR S&P Pharmaceuticals ETF
Index- P/E- EPS (ttm)- Insider Own- Shs Outstand- Perf Week-0.14%
Market Cap- Forward P/E- EPS next Y- Insider Trans- Shs Float- Perf Month-7.27%
Income- PEG- EPS next Q- Inst Own- Short Float- Perf Quarter-7.77%
Sales- P/S- EPS this Y- Inst Trans- Short Ratio8.22 Perf Half Y-1.90%
Book/sh- P/B- EPS next Y- ROA- Target Price- Perf Year-10.43%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range37.31 - 55.69 Perf YTD-17.27%
Dividend0.20 P/FCF- EPS past 5Y- ROI- 52W High-23.93% Beta-
Dividend %0.47% Quick Ratio- Sales past 5Y- Gross Margin- 52W Low13.54% ATR0.74
Employees- Current Ratio- Sales Q/Q- Oper. Margin- RSI (14)39.12 Volatility1.11% 1.67%
OptionableYes Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.77 Prev Close42.20
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume119.85K Price42.36
Recom- SMA20-2.99% SMA50-5.68% SMA200-2.08% Volume92,657 Change0.38%
Oct-20-16 05:48PM  Another Health Care Chart Looks Sick
08:04AM  Eli Lilly and Co.s 3Q16 Estimates: Cardiovascular Franchise
Oct-12-16 10:04AM  BMYs Drug Treatments That Go beyond Immuno-Oncology
Oct-10-16 11:04AM  Keytruda Leads over Opdivo in Head and Neck Cancer Treatment
Oct-04-16 10:04AM  A Look at Gardasil and Merck & Co.s Vaccines Business
Oct-03-16 08:05AM  Medicare Negotiations Would Lead to Huge Cost Savings
Sep-30-16 03:04PM  Analyzing Donald Trumps Free-Market Healthcare
11:15AM  Generic Drugs Are Crucial in Cost Savings and Accessibility
Sep-27-16 02:20PM  Getting Into The Drug Business: From NDAs To PDUFA Dates
Sep-26-16 11:05AM  How Mylans Profitability Has Changed
Sep-23-16 03:20PM  Are Mylans EpiPen Challenges Souring Analysts Views on Stock?
02:23PM  Pharma ETF Looks Healthy in a Sick Market After Endo Names New CEO
Sep-21-16 11:05AM  How Analysts See Horizon Compared to Its Peers
Sep-20-16 12:04PM  News of Acquisition Caused Horizon Pharma Stock to Rise
Sep-19-16 06:50PM  A Breakdown Here In This Sector Would Not Be Healthy
Sep-12-16 02:47PM  M&A Activity, Passing Drug Trials Help Biotech ETFs Rebound
09:30AM  The Zacks Analyst Blog Highlights: Powershares Dynamic Pharmaceuticals ETF, SPDR S&P Pharmaceuticals ETF, iShares U.S. Pharmaceuticals and Market Vectors Pharmaceutical
Sep-09-16 03:39PM  Will a Clinton Presidency Spell Doom for Pharma ETFs?
Sep-06-16 11:22AM  Top Sector ETFs of Summer
Sep-05-16 11:04AM  Animal Health: Just as Important to Eli Lilly as Human Health
Aug-31-16 10:05AM  Why Pfizer Is Trading at a Discount on an Earnings Basis
Aug-30-16 10:04AM  Akorn in 2016: What Are Its Key Risk Factors?
Aug-24-16 11:04AM  How Did Bristol-Myers Squibb Fare in 2Q16?
Aug-22-16 09:06AM  How Did Bristol-Myers Squibbs Oncology Segment Perform in 2Q16?
Aug-19-16 11:04AM  Horizons Orphan Drug Business Faces These Opportunities
Aug-15-16 09:06AM  What Are Mercks Key Diabetes Products?
Aug-07-16 01:20PM  Obamacare Still Sickly, After All These Years
Aug-04-16 09:04AM  Eli Lillys Cardiovascular Franchise Keeps Posting Upbeat Revenues
Aug-03-16 12:22PM  Pharma ETFs Soaring on Solid Q2 Earnings
Jul-26-16 09:04AM  What Key Developments Did JNJ Announce in 2Q16?
Jul-25-16 02:24PM  Expectations for Bristol-Myers Squibbs 2Q16 Earnings
Jul-22-16 01:07PM  Inside Lillys 2Q16 Estimates for Its Cardiovascular Franchise
Jul-21-16 11:08AM  Best Sector ETFs for Q3
Jul-15-16 09:06AM  Jazz Pharmaceuticals: How Much Return Potential Does It Have?
Jul-12-16 11:06AM  Check out Horizons Huge Upside Potential
Jul-07-16 07:06AM  Whats Really Driving Horizons Valuation?
May-20-16 10:05AM  Keytruda: Mercks Immuno-Oncology Blockbuster Drug
09:30AM  Pharmaceuticals & Emerging Market: Two ETFs Trading with Outsized Volume
May-12-16 10:09AM  Januvia and Janumet: Mercks Blockbuster Diabetes Drugs
May-11-16 03:47PM  Mercks Valuation Cheat Sheet for Fiscal 1Q16
May-07-16 10:01AM  Mudslinging Over Valeant Pharmaceuticals
May-05-16 08:05PM  How Eli Lillys Cardiovascular Franchise Performed in 1Q16
May-04-16 02:50PM  Pharma ETFs Outlook -- Drug Pricing Issues Remain in Focus
09:00AM  Finding Pharmaceuticals ETFs With Rebound Potential
Apr-26-16 07:08PM  What Do Analysts Recommend for Jazz Pharmaceuticals?
Apr-20-16 06:06PM  Analyzing Akorns Strategy to Withstand Generic Industry Challenges
Apr-11-16 01:04AM  Is Mallinckrodt Spending Enough on R&D?
Apr-06-16 12:05PM  Your Horizon Breakdown: Performance across Segments
11:36AM  3 ETFs to Watch (XLF, IEV) at Investopedia
Mar-28-16 03:39PM  How Horizon Became a Growth Stock
Mar-24-16 01:26PM  Mylan Expected to Further Strengthen EpiPen Franchise in 2016
Mar-23-16 02:09PM  Where Else Have We Seen Mallinckrodts Acquire to Invest Strategy?
Mar-21-16 09:01AM  Better Buy: Intuitive Surgical, Inc. vs. Medtronic PLC at Motley Fool
Mar-18-16 08:07AM  Better Buy: AbbVie Inc. vs. Eli Lilly at Motley Fool
Mar-17-16 09:21AM  The 5-Minute Guide to Horizon Pharma PLC Stock at Motley Fool
Mar-12-16 08:25PM  Saturday links: poised for growth
Mar-09-16 06:37AM  5 Best Performing Bull Run Equity ETFs
Jan-28-16 12:04PM  Insight into Tevas Over-the-Counter and Distribution Businesses
Jan-04-16 01:50PM  What Does 2016 Hold in Store for Pharma ETFs
Dec-14-15 01:20PM  FEZ and EWJ Fall as Crude Oil Prices Plunge Further
Dec-09-15 05:54PM  DuPont-Dow Megadeal Talk Stirs Materials ETFs at Investor's Business Daily
08:06AM  Kite Pharma Leads IBBs Mid-Caps on Its Zuma-1 Phase 1 Results
Dec-08-15 06:56PM  Oil ETFs Dig A Hole But Could Syria Change That? at Investor's Business Daily
01:06PM  Consumer Staples Didnt Fall into Equity Markets Downtrend
01:03PM  SPY Ended Negative as Oil Sank to New Lows
12:07PM  Alexion Tops IBBs Large-Caps on Release of New Research Data
11:55AM  U.S. benchmarks rattle the cage on important support at MarketWatch
Dec-07-15 06:13PM  Jet ETF Climbs, Dow In Red For 2015 As Oil Weighs at Investor's Business Daily
05:34PM  Financial Sector Catches a Rate Hike Tailwind on December 4
05:34PM  Gung-Ho US Employment Scene Catapults SPY on December 4
03:45PM  How Are IBBs American Depositary Receipts Performing?
11:52AM  FEZ Rises by 1.2% on Strong Employment Data
07:05AM  IHIs Small Caps Outperformed the Market
07:05AM  Abiomed Rose 1% on High Trading Volume
Dec-05-15 07:40AM  These 3 ETFs Jumped in November at Motley Fool
12:01AM  [$$] Funds' Warmth Faces Cold Shoulders at
Dec-04-15 06:23PM  Gold Mining ETFs Spike As Metal Shines at Investor's Business Daily
03:07PM  Mallinckrodt Rose after Sale of Contrast Media & Delivery System
02:06PM  Rate Hike Hints Boost November Fund Flows of $731 Million in XLF
01:01PM  How Did Cooper Companies and Its Peers Perform?
01:00PM  Cooper Companies Income Rose in Fiscal 4Q15
12:22PM  Sell-Off in All the Component Sectors of the SPY ETF
12:22PM  Draghis Dovish Move Was Less than Expected, Affecting US Stocks
12:06PM  Investors Have Pulled $54 Million from KCE in 2015
12:06PM  Investors Have Added $247 Million to KIE in 2015
10:48AM  The ECB Disappoints Markets with Its Monetary Policy Decisions
10:36AM  Markets Jump On Strong Jobs Numbers; Economist Says This Signals First Rate Hike In Seven Years
07:00AM  A Low-Cost ETF Offering Exposure to U.S. Banks at Morningstar
Dec-03-15 07:30PM  Chip ETFs Cool As Ambarella Sinks; Dollar Dives at Investor's Business Daily
04:04PM  Patterson Reports Fiscal 2Q16 Earnings, Drags Down Mid-Caps
01:46PM  FEZ and EWJ Fall following a Global Commodity and Equity Sell-Off
12:49PM  Should the Euro Rally Affect U.S. Stocks?
12:40PM  Waters Fell on Profit Booking and Hurt IHIs Large Caps
12:38PM  Fed Chairs Hawkish Tone on Rate-Hike Led SPY Lower
09:30AM  The Zacks Analyst Blog Highlights: First Trust NASDAQ Global Auto ETF, iShares Dow Jones Transportation Average Fund, SPDR S&P Regional Banking ETF and PowerShares S&P SmallCap Utilities ETF
Dec-02-15 02:51PM  SPY Rallies as Economic Data Turn Out to Be Mixed
10:07AM  Geron to Present at Two Conferences, Stock Jumps 13%
10:06AM  Investors Poured $268 Million into KRE in November
10:06AM  KBE Witnessed Inflows of $41 Million in November
08:44AM  Insurance ETF (KIE) Hits New 52-Week High
The investment seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of an index derived from the pharmaceuticals segment of a U.S. total market composite index. In seeking to track the performance of the S&P Pharmaceuticals Select Industry Index (the "index"), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the pharmaceuticals industry group of the S&P Total Market Index ("S&P TMI"). The fund is non-diversified.